Farallon Capital Management’s Vaxcyte PCVX Stock Holding History

Farallon Capital Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,261,000	Closed	-$73.3M	–	159
2026 Q1	$73.3M	Buy	1,261,000 +1,256,000	+25,120%	+$68.2M	0.38%	38
2025 Q4	$231K	Buy	+5,000	New	+$224K	﹤0.01%	127
2024 Q4	–	Sell	-28,000	Closed	-$3.2M	–	164
2024 Q3	$3.2M	Sell	28,000 -262,000	-90%	-$23.6M	0.01%	98
2024 Q2	$21.9M	Sell	290,000 -87,400	-23%	-$5.95M	0.09%	72
2024 Q1	$25.8M	Buy	377,400 +374,000	+11,000%	+$25.9M	0.11%	66
2023 Q4	$214K	Buy	+3,400	New	+$177K	﹤0.01%	127

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Farallon Capital Management's PCVX Position: Q2 2026 in Review

Farallon Capital Management sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 1,261,000 shares — an estimated $73.3M sold.

Farallon Capital Management first reported a position in PCVX in Q4 2023 and held it in 6 quarters. The position peaked at $73.3M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Farallon Capital Management reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
Farallon Capital Management sold 1,261,000 Vaxcyte shares in Q2 2026, an estimated $73.3M.
Farallon Capital Management first reported a position in Vaxcyte in Q4 2023 and held it in 6 quarters.
Farallon Capital Management's Vaxcyte position peaked at $73.3M in Q1 2026.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Farallon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.